当前位置：
X-MOL 学术
›
Eur. J. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
IL-33/ST2 as a potential target for tumor immunotherapy
European Journal of Immunology ( IF 4.5 ) Pub Date : 2021-06-15 , DOI: 10.1002/eji.202149175 Wenyi Jiang 1, 2 , Jingyao Lian 1, 2 , Ying Yue 3 , Yi Zhang 1, 2, 4
European Journal of Immunology ( IF 4.5 ) Pub Date : 2021-06-15 , DOI: 10.1002/eji.202149175 Wenyi Jiang 1, 2 , Jingyao Lian 1, 2 , Ying Yue 3 , Yi Zhang 1, 2, 4
Affiliation
|
IL-33, a member of the IL-1 family, was initially reported to be expressed constitutively in the nucleus of tissue-lining and structural cells. However, upon tissue damage or injury, IL-33 can be released quickly to bind with its cognate receptor ST2 in response to wound healing and inflammation and act as a DAMP. As a key regulator of Th2 responses, IL-33/ST2 signal is primarily associated with immunity and immune-related disorders. In recent years, IL-33/ST2 signaling pathway has been reported to promote the development of cancer and remodel the tumor microenvironment by expanding immune suppressive cells such as myeloid-derived suppressor cells or regulatory T cells. However, its role remains controversial in some tumor settings. IL-33 could also promote effective infiltration of immune cells such as CD8+ T and NK cells, which act as antitumor. These dual effects may limit the clinical application to target this cytokine axis. Therefore, more comprehensive exploration and deeper understanding of IL-33 are required. In this review, we summarized the IL-33/ST2 axis versatile roles in the tumor microenvironment with a focus on the IL-33-target immune cells and downstream signaling pathways. We also discuss how the IL-33/ST2 axis could be used as a potential therapeutic target for cancer immunotherapy.
中文翻译：
IL-33/ST2 作为肿瘤免疫治疗的潜在靶点
IL-33 是 IL-1 家族的成员，最初据报道在组织衬里和结构细胞的细胞核中组成型表达。然而，在组织损伤或损伤时，IL-33 可以快速释放以与其同源受体 ST2 结合，以响应伤口愈合和炎症，并充当 DAMP。作为 Th2 反应的关键调节因子，IL-33/ST2 信号主要与免疫和免疫相关疾病有关。近年来，有报道称 IL-33/ST2 信号通路通过扩增髓源性抑制细胞或调节性 T 细胞等免疫抑制细胞来促进癌症的发展并重塑肿瘤微环境。然而，它在某些肿瘤环境中的作用仍然存在争议。IL-33还可以促进CD8 +等免疫细胞的有效浸润T 细胞和 NK 细胞，它们起到抗肿瘤作用。这些双重作用可能会限制针对该细胞因子轴的临床应用。因此，需要对IL-33进行更全面的探索和更深入的了解。在这篇综述中，我们总结了 IL-33/ST2 轴在肿瘤微环境中的多功能作用，重点是 IL-33 目标免疫细胞和下游信号通路。我们还讨论了如何将 IL-33/ST2 轴用作癌症免疫疗法的潜在治疗靶点。
更新日期：2021-08-05
中文翻译：
IL-33/ST2 作为肿瘤免疫治疗的潜在靶点
IL-33 是 IL-1 家族的成员，最初据报道在组织衬里和结构细胞的细胞核中组成型表达。然而，在组织损伤或损伤时，IL-33 可以快速释放以与其同源受体 ST2 结合，以响应伤口愈合和炎症，并充当 DAMP。作为 Th2 反应的关键调节因子，IL-33/ST2 信号主要与免疫和免疫相关疾病有关。近年来，有报道称 IL-33/ST2 信号通路通过扩增髓源性抑制细胞或调节性 T 细胞等免疫抑制细胞来促进癌症的发展并重塑肿瘤微环境。然而，它在某些肿瘤环境中的作用仍然存在争议。IL-33还可以促进CD8 +等免疫细胞的有效浸润T 细胞和 NK 细胞，它们起到抗肿瘤作用。这些双重作用可能会限制针对该细胞因子轴的临床应用。因此，需要对IL-33进行更全面的探索和更深入的了解。在这篇综述中，我们总结了 IL-33/ST2 轴在肿瘤微环境中的多功能作用，重点是 IL-33 目标免疫细胞和下游信号通路。我们还讨论了如何将 IL-33/ST2 轴用作癌症免疫疗法的潜在治疗靶点。
京公网安备 11010802027423号